RT期刊文章SR电子T1风险因素控制和医生之间的关系专业Crest-2试验(P6.001)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P6.001 VO 90 15 A1谭雅图兰补充A1詹姆斯Meschia A1珍妮弗Voe首页ks A1凯文·巴雷特A1罗伯特•布朗A1 Seemant查图尔维迪A1 Marc Chimowitz A1巴特Demaerschalk A1您正在Emmady A1乔治A1弗吉尼亚霍华德A1约翰·休斯顿A1迈克尔·琼斯A1 Brajesh Lal A1罗纳德•拉扎尔A1韦斯利·摩尔A1克劳迪娅Moy A1安娜Roldan称A1加里Roubin A1托马斯王硕年2018 UL //www.ez-admanager.com/content/90/15_Supplement/P6.001.abstract AB目的:分析血管危险因素之间的关系控制在早期随访和医生特点在临床试验中评估无症状的颈动脉狭窄的优化管理。背景:在CREST2,密集的医疗管理的受试者的血管危险因素是由网站的首席研究员(π)和由指定医疗管理实现医生(MMP)和协调员。这些医生有不同的专长和经验与风险因素的管理。我们试图确定风险因素之间的关系控制和PI和MMP的专业。设计/方法:613例至少1后续访问数据从105年CREST2网站被用于这些分析。CREST2网站分类基于π专业和MMP的专业。专业的site-designated主要MMP与多个MMP用于网站。我们比较患者的百分比目标在最后的随访中主要风险因素,低密度脂蛋白< 70 mg / dL, SBP < 140毫米汞柱,在π专业和MMP的专业中,使用卡方检验。结果:没有明显差异控制SBP或低密度脂蛋白π专业。有一个趋势之间的关联的低密度脂蛋白控制和MMP的专业,与较高的低密度脂蛋白控制站点与内科MMP的专家和较低的控制与血管手术基质金属蛋白酶。SBP在MMP的专业控制率没有显著差异。结论:早期分析风险因素控制在CREST2研究中,站点π和MMP的专业没有显著影响LDL和SBP在随访中。 This suggests that protocol care pathways are generalizable to diverse physicians.Disclosure: Dr. Turan has nothing to disclose. Dr. Meschia has nothing to disclose. Dr. Voeks has nothing to disclose. Dr. Barrett has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Chaturvedi has received personal compensation in an editorial capacity for NEJM Journal Watch Neurology. Dr. Chaturvedi has received research support from Boehringer Ingelheim. Dr. Chimowitz has nothing to disclose. Dr. Demaerschalk has nothing to disclose. Dr. Emmady has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Huston has nothing to disclose. Dr. Jones has nothing to disclose. Dr. Lal has nothing to disclose. Dr. Lazar has nothing to disclose. Dr. Moore has nothing to disclose. Dr. Moy has nothing to disclose. Dr. Roldan has nothing to disclose. Dr. Roubin has nothing to disclose. Dr. Brott has nothing to disclose.

map